{"id":"formoterol-fumerate","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1256786","moleculeType":"Small molecule","molecularWeight":"344.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. As a long-acting formulation, it provides extended symptom relief and airway opening for 12 hours or longer, making it suitable for maintenance therapy in chronic obstructive pulmonary disease and asthma.","oneSentence":"Formoterol fumarate is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:47.434Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of asthma"},{"name":"Maintenance treatment of chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT01641081","phase":"PHASE2","title":"Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Asthma","enrollment":174},{"nctId":"NCT00460577","phase":"PHASE4","title":"Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Acute Bronchial Obstruction, Asthma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":9,"reaction":"DYSPNOEA"},{"count":8,"reaction":"ASTHMA"},{"count":7,"reaction":"WHEEZING"},{"count":6,"reaction":"THERAPEUTIC PRODUCT EFFECT INCOMPLETE"},{"count":3,"reaction":"BRONCHIECTASIS"},{"count":3,"reaction":"CHEST DISCOMFORT"},{"count":3,"reaction":"COUGH"},{"count":3,"reaction":"FATIGUE"},{"count":3,"reaction":"OBSTRUCTIVE AIRWAYS DISORDER"},{"count":2,"reaction":"ANAEMIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Formoterol fumerate","genericName":"Formoterol fumerate","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formoterol fumarate is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Maintenance treatment of asthma, Maintenance treatment of chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}